article
CRISPR-Cas9 repairs genetic mutation in human embryos
"Well thought through and brilliantly executed" study shows different DNA-repair mechanism in embryos compared to iPSCs
List view / Grid view
CRISPR
article
David F Fischer on target screening
Drug Target Review editor Steve Bremer asks David F Fischer for his views on target discovery and validation in drug discovery. David F Fischer, PhD, is Executive Director Biology at Charles River...
article
New drug targets identified to defend against chlamydia infections using CRISPR and stem cells
Human induced pluripotent stem cell derived macrophages (iPSDMs) provide a cell-based model system to study chlamydia infection in the laboratory. Amy Yeung from Wellcome Trust Sanger Institute explains how she used this model in combination with CRISPR-Cas 9 technology to explore the potential of the two genes, IRF5 and IL10RA,…
news
CRISPR gene editing can cause hundreds of unintended mutations
As CRISPR-Cas9 starts to move into clinical trials, a new study has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome.
news
Oxford Genetics licenses CRISPR technology for biotherapeutic discovery
Licensing agreement will expand Oxford Genetics growing bio-therapeutic discovery, design and development service business.
news
New chlamydia drug targets discovered using CRISPR and stem cells
Scientists have created an innovative technique for studying how chlamydia interacts with the human immune system...
news
New potential treatment for aggressive brain cancer in children
Using state-of-the-art gene editing technology, scientists have discovered a promising target to treat atypical teratoid/rhabdoid tumour (AT/RT) - a highly aggressive and therapy resistant brain tumour that mostly occurs in infants.
news
Premature cell differentiation leads to disorders in pancreatic development
Neonatal diabetes mellitus (NDM), or diabetes among infants less than six months of age, is a rare form of diabetes caused by a mutation in genes crusial to the development or function of beta cells. In about half of such cases, the disease becomes permanent (PNDM). Mutations in more than…
news
Charles River Laboratories announces launch of triple-immunodeficient mouse model for oncology research
Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model...
webinar
Vertical integration of CRISPR/Cas9 in drug discovery
10 February 2017 | By Charles River
In this webinar, Charles River discuss the utilisation of CRISPR/Cas9 technology in drug discovery, with an emphasis on generation of in vitro models for high-throughput screening, and creating new mouse models...
news
Enhanced CRISPR allows exploration of disease in every cell type
2 December 2016 | By Niamh Louise Marriott, Digital Editor
These systems will allow researchers worldwide to rapidly and accurately explore the changing role of genes as the cells develop into tissues...
news
Charles River demonstrates CRISPR/Cas9 genome engineering expertise
2 December 2016 | By Charles Rivers Laboratories
Charles River Laboratories has launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology...
article
C is for CRISPR
16 November 2016 | By Niamh Louise Marriott, Digital Content Producer
C is for CRISPR - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research of CRISPR technology
news
Vulnerabilities of leukaemia cells revealed using CRISPR genome editing technique
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers from the Wellcome Trust have adapted a CRISPR gene editing technique and used it to find new therapeutic targets for acute myeloid leukaemia...
webinar
Use of IntelliCyt’s iQue Screener for high-throughput screening of small molecules, CRISPRs and stem cells
29 September 2016 | By Intellicyt
This webinar highlights the use of the iQue Screener for high-throughput screening of stem cells, small molecules and CRISPR functional screening, presented by David Sykes, M.D., Ph.D., Researcher from Massachusetts General Hospital and Thibault Jonckheere, CEO and Séverine Giltaire, Senior Scientist from ImmunXperts...